SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001628280-24-029969 from GRI Bio, Inc. (GRI)

GRI Bio, Inc.
Date: June 25, 2024 · CIK: 0001824293 · Accession: 0001628280-24-029969

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-280323

Date
June 25, 2024
Author
W. Marc Hertz, Ph.D.
Form
CORRESP
Company
GRI Bio, Inc.

Letter

Document

GRI BIO, INC.

2223 AVENIDA DE LA PLAYA, SUITE 208

LA JOLLA, CA 92037

VIA EDGAR

June 25, 2024

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Daniel Crawford

Re:

GRI Bio, Inc.

Registration Statement on Form S-1 (Reg. No. 333-280323)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, GRI Bio, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) so that the Registration Statement will be declared effective as of 5:15 p.m. Eastern time, on June 26, 2024, or as soon as practicable thereafter. The Company hereby authorizes Melanie Ruthrauff Levy or Jason Miller, both of whom are attorneys at the Company’s outside legal counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., to orally modify or withdraw this request for acceleration.

Once the Registration Statement has been declared effective, please orally confirm that event with Mrs. Levy at (858) 314-1873 or Mr. Miller at (858) 314-2140.

Thank you for your assistance in this matter.

Very truly yours,
GRI BIO, INC.

Show Raw Text
CORRESP
1
filename1.htm

Document

GRI BIO, INC.

2223 AVENIDA DE LA PLAYA, SUITE 208

LA JOLLA, CA 92037

VIA EDGAR

June 25, 2024

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Daniel Crawford

Re:

 GRI Bio, Inc.

 Registration Statement on Form S-1 (Reg. No. 333-280323)

 Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, GRI Bio, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) so that the Registration Statement will be declared effective as of 5:15 p.m. Eastern time, on June 26, 2024, or as soon as practicable thereafter. The Company hereby authorizes Melanie Ruthrauff Levy or Jason Miller, both of whom are attorneys at the Company’s outside legal counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., to orally modify or withdraw this request for acceleration.

Once the Registration Statement has been declared effective, please orally confirm that event with Mrs. Levy at (858) 314-1873 or Mr. Miller at (858) 314-2140.

Thank you for your assistance in this matter.

Very truly yours,

GRI BIO, INC.

/s/ W. Marc Hertz, Ph.D.

W. Marc Hertz, Ph.D.

Chief Executive Officer

cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

 Melanie Ruthrauff Levy, Esq.

 Jason Miller, Esq.